ASH 2021 | Looking forward to ASH 2021: key updates in DLBCL

Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, gives an overview of the main updates in diffuse large B-cell lymphoma (DLBCL) that will be discussed at the upcoming ASH annual meeting. To begin with, the data from the POLARIX trial comparing the efficacy of polatuzumab vedotin plus R-CHP versus R-CHOP in previously untreated DLBCL (NCT03274492) is eagerly awaited, as a recent press release reported that the primary endpoint was met. In addition, updates from the ZUMA-7 study investigating the efficacy of axicabtagene ciloleucel versus standard of care (SOC) in relapsed/refractory DLBCL (NCT03391466) will be presented at ASH, as well as new exciting data on bispecific antibodies for lymphoma. Dr Collins is also looking forward to hearing more details about the real-world data from a study evaluating the outcomes of different central nervous system (CNS) prophylaxis strategies in DLBCL which could have a substantial impact on clinical practice. Finally, an interesting study investigating the use of cell-free DNA (cfDNA) as a diagnostic and prognostic biomarker in primary CNS lymphoma will be presented at the Plenary Scientific Session. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.